{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"50.0","upperLimit":"100.0","value":"83.3"},{"groupId":"OG001","lowerLimit":"39.8","upperLimit":"96.6","value":"68.2"}]}],"title":"PFS at 1 year"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"60.5","value":"27.8"},{"groupId":"OG001","lowerLimit":"0.0","upperLimit":"72.5","value":"34.1"}]}],"title":"PFS at 2 years"}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"11"}],"units":"Participants"}],"description":"PFS estimates for each stratum were estimated using the method of Kaplan and Meier. PFS was defined as the time interval from date on treatment to the earliest date of disease progression, second malignancy, or death; or to date of last contact for patients without events. One- and two-year PFS estimates are reported by stratum. Only eligible patients were included in this analysis (7 stratum 1 patients and 11 stratum 2 patients).","dispersionType":"95% Confidence Interval","groups":[{"description":"Stratum 1 patients are those with progressive unresectable or recurrent craniopharyngiomas treated with surgery alone, who had not received radiation therapy. Treatment consisted of Peginterferon alfa-2b (Sylatron) subcutaneously weekly for 6 weeks. Treatment may repeat every 6 weeks for up to 18 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Stratum 1"},{"description":"Stratum 2 patients are those with patients with progressive or recurrent craniopharyngiomas following radiation therapy. Treatment consisted of Peginterferon alfa-2b (Sylatron) subcutaneously weekly for 6 weeks. Treatment may repeat every 6 weeks for up to 18 courses in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Stratum 2"}],"paramType":"NUMBER","populationDescription":"The one ineligible stratum 2 patient enrolled on the study was excluded from this analysis, leaving 7 stratum 1 patients and 11 stratum 2 patients.","reportingStatus":"POSTED","timeFrame":"2 years after treatment start","title":"Progression-free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"percentage of participants"}